4//SEC Filing
STEPHENSON BRIAN C 4
Accession 0000950170-25-023630
CIK 0001743881other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:50 PM ET
Size
17.9 KB
Accession
0000950170-25-023630
Insider Transaction Report
Form 4
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Transactions
- Exercise/Conversion
Common Stock
2025-02-16+25,798→ 119,714 total - Tax Payment
Common Stock
2025-02-16$34.90/sh−13,102$457,260→ 106,612 total - Sale
Common Stock
2025-02-19$36.16/sh−4,148$149,973→ 102,464 total - Exercise/Conversion
Restricted Stock Units
2025-02-16−779→ 0 total→ Common Stock (779 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−946→ 2,840 total→ Common Stock (946 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−17,368→ 138,947 total→ Common Stock (17,368 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−6,705→ 80,459 total→ Common Stock (6,705 underlying)
Footnotes (9)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Includes 158 shares of the Issuer's Common Stock acquired by the Reporting Person on February 14, 2025 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
- [F3]Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,798 shares of Common Stock underlying the Reporting Person's RSUs.
- [F4]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
- [F5]Represents the weighted average sale price of the shares sold from $35.57 to $36.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vested on a quarterly basis. The RSUs have no expiration date.
- [F7]The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- [F8]The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- [F9]The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001780030
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 8:50 PM ET
- Size
- 17.9 KB